The phase 2 multicenter TROPION-PanTumor study was designed to evaluate the efficacy of TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) as…
en_news
Advances driven by research have led to significant developments in better understanding the molecular taxonomy of cancer and therapeutic breakthroughs…
Presented today at the ESMO Congress 2024* by Maria Vieito, Medical Oncologist at the Vall d’Hebron University Hospital, CORE Phase…
Among the 518 women enrolled in the international POSITIVE clinical trial with hormone receptor-positive early breast cancer who temporarily interrupted…
Researchers from VHIO are participating in an international study led by IRB Barcelona that identifies five independent factors predicting cancer…
Published open access in Genome Medicine, results of a study led by VHIO’s Experimental Therapeutics Group further support the use…
Based on results from the CAPITello-291 phase III study, co-led by VHIO’s Mafalda Oliveira, Senior Medical Oncologist at Vall d’Hebron…
Results of the phase III LITESPARK-005 clinical trial show that treatment with belzutifan versus everolimus significantly improves progression-free survival in…
Now published in Annals of Oncology (1), updated meta-analysis provides insights into the efficacy of adoptive cell therapy with tumor-infiltrating…
Results of a preclinical, proof-of-concept study led by VHIO’s Stem Cells and Cancer Group demonstrate for the first time the…
